Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus albumin-bound paclitaxel and cisplatin as neoadjuvant therapy for resectable oral squamous cell carcinoma
ChiCTR2500115521Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Oral Mucosal Carcinoma, sponsored by Hunan Cancer Hospital. Primary endpoints: Pathological complete response rate (pCR), Overall survival (OS) and 3 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2500115521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115521.